The failure of United Therapeutics Corp.'s beraprost oral prostacyclin analog in a Phase III trial leaves the company banking on the pending approval of its injectable Remodulin prostacyclin analog to take it to profitability, while it looks to deploy its $180 million in cash to beef up its clinical pipeline with compounds in mid- to late-stage development.

Last week, UTHR (Silver Spring, Md.) said it expects to halt development of beraprost for intermittent claudication (pain when walking) from peripheral vascular disease (PVD) after data from a 750-patient U.S. Phase III trial failed to confirm